Financial Statements and Performance Highlights of Emcure Pharmaceuticals
Financial Summary
For the financial year ending on 31 March 2022, Emcure Pharmaceuticals Limited (Emcure) reported a significant surge in revenue of 11.33%, reaching Rs. 6,715 crore.
Revenue Breakdown
Emcure's revenue streams include both India and international sales. In India, the company generated Rs. 4,828 crore, accounting for 48.28% of its total revenue. Sales outside India contributed Rs. 3,443.35 crore, reflecting a CAGR of 13.97% from FY2022 to FY2024.
Profitability
Despite the revenue growth, Emcure's net profit after tax (PAT) experienced a decline of 6.1%. The company's net profit stood at Rs. 561.85 crore for the year ending March 2022.
Manufacturing Facilities
Emcure Pharmaceuticals operates 13 manufacturing facilities across India.
Recent Developments
Emcure Pharmaceuticals' initial public offering (IPO) opened for subscription on July 3, 2024.
Competitors' Financial Performance
- Gennova Biopharmaceuticals Ltd: Financial Statement 2022
- Zuventus Healthcare: Financial Statement 2021
Comments